Genmab A/S (Nasdaq: GMAB) announced that worldwide net trade sales of DARZALEX (daratumumab) totaled $4,239 million in the third quarter of 2026, according to figures reported by Johnson & Johnson.

U.S. net trade sales reached $2,528 million, while sales in the rest of the world totaled $1,711 million. The figures include sales of the subcutaneous product, daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO in the U.S.

Genmab receives royalties on worldwide net sales of DARZALEX, covering both intravenous and subcutaneous products, under an exclusive worldwide license granted to Johnson & Johnson's legal entity Janssen Biotech, Inc. to develop, manufacture, and commercialize daratumumab.